Patents by Inventor Vivekananda M. Vrudhula

Vivekananda M. Vrudhula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic kinase inhibitors
    Patent number: 10035777
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: July 31, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Bireshwar Dasgupta, Susheel Jethanand Nara, Vivekananda M. Vrudhula, Senliang Pan, Richard A. Hartz, Ramkumar Rajamani
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20170260145
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: July 27, 2015
    Publication date: September 14, 2017
    Inventors: Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Bireshwar Dasgupta, Susheel Jethanand Nara, Vivekananda M Vrudhula, Senliang Pan, Richard A. Hartz, Ramkumar Rajamani
  • GSK-3 inhibitors
    Patent number: 9718804
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: August 1, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Vivekananda M. Vrudhula, Senliang Pan, Prasanna Sivaprakasam, John E. Macor
  • Aryl amide-based kinase inhibitors
    Patent number: 9708337
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani, Maheswaran Sivasamban Karatholuvhu
  • ARYL LACTA KINASE INHIBITORS
    Publication number: 20160333006
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: January 29, 2014
    Publication date: November 17, 2016
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L. Ditta, Carolyn Diane Dzierba, Joanne J Bronson, John E. Macor
  • GSK-3 INHIBITORS
    Publication number: 20160272621
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Application
    Filed: November 3, 2014
    Publication date: September 22, 2016
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Vivekananda M. Vrudhula, Senliang Pan, Prasanna Sivaprakasam, John E. Macor
  • ARYL ETHER-BASE KINASE INHIBITORS
    Publication number: 20160222021
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 4, 2016
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • ARYL AMIDE-BASED KINASE INHIBITORS
    Publication number: 20160016967
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: February 6, 2014
    Publication date: January 21, 2016
    Inventors: Vivekananda M. Vrudhula, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani, Maheswaran Sivasamban Karatholuvhu
  • Aryl ether-base kinase inhibitors
    Patent number: 8969564
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Aryl lactam kinase inhibitors
    Patent number: 8901305
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: December 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L. Ditta, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor
  • Aryl Ether-Base Kinase Inhibitors
    Publication number: 20140179725
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 26, 2014
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Aryl ether-base kinase inhibitors
    Patent number: 8703953
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Aryl Lactam Kinase Inhibitors
    Publication number: 20140038999
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 6, 2014
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu, Tarun Kumar Maishal, Jonathan L. Ditta, Carolyn Diane Dzierba, Joanne J. Bronson, John E. Macor
  • Aryl Ether-Base Kinase Inhibitors
    Publication number: 20130237555
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: February 26, 2013
    Publication date: September 12, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Pyrazinone modulator of corticotropin-releasing factor receptor activity
    Patent number: 8372847
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: February 12, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • Substituted heterocyclic ethers and their use in CNS disorders
    Patent number: 8026257
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: September 27, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, George O. Tora, Derek J. Denhart, Vivekananda M. Vrudhula, John E. Macor, Joanne J. Bronson
  • Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity
    Publication number: 20110166160
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 7, 2011
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • ()-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
    Patent number: 7932256
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: April 26, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity
    Publication number: 20100029684
    Abstract: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.
    Type: Application
    Filed: April 24, 2009
    Publication date: February 4, 2010
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Vivekananda M. Vrudhula, Joanne J. Bronson
  • Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
    Patent number: 7572795
    Abstract: Compounds having the Formula (I), including pharmaceutically acceptable salts thereof, wherein at least one of X1, X2 or X3 is and any remaining X1, X2 or X3 is hydrogen, which are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, A1, A2 and m are as described herein.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: August 11, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Katerina Leftheris, Vivekananda M. Vrudhula, James Lin